The 1 analysts offering 12-month price forecasts for Bellicum Pharmaceuticals Inc have a median target of 4.50, with a high estimate of 4.50 and a low estimate of 4.50. The median estimate represents a +154.24% increase from the last price of 1.77.
The current consensus among 1 polled investment analysts is to Hold stock in Bellicum Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.57
Reporting Date Mar 14
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.